News
Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Novartis has announced that its interleukin-1beta (IL-1β) inhibitor canakinumab failed to hit the primary endpoint of overall survival in a Phase III non-small cell lung cancer (NSCLC) trial.